CUSTOMIZE: Implementation-Effectiveness Study of Long-Acting Cabotegravir and Rilpivirine Injection in US Healthcare Settings

July 18-21, 2021; Virtual
In this real-world study, healthcare staff across a variety of clinic types found the implementation of monthly injectable cabotegravir + rilpivirine both feasible and acceptable despite disruptions due to COVID-19.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Karen Ha and Clinical Care Options (CCO): Data suggests there is a role for NNRTIs in current practice, including for patients who have experienced weight gain with INSTI-based ART.

Karen Ha, MD Released: December 6, 2021

Slides from Dr Milena Murray and Clinical Care Options (CCO): Data suggests patient factors that may inform candidacy for LA CAB + RPV as a treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: December 1, 2021

Expert commentary on what long-acting ART means for people with HIV, from Dr Jean-Michel Molina and Clinical Care Options (CCO)

Jean-Michel Molina, MD, PhD Released: November 30, 2021

Commentary from Dr Karine Lacombe on the potential role of an investigational 2-drug regimen of lenacapavir plus islatravir, from Clinical Care Options (CCO)

Karine Lacombe, MD, PhD Released: November 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue